ABVC BioPharma Raises $3.39M via 17.5% OID Convertible Notes
JERSEY CITY – November 02, 2026 -- ABVC BioPharma (NASDAQ: ABVC) has closed a private placement of original issue discount senior convertible promissory notes that generated approximately $3.39 million in gross proceeds, before placement agent fees and offering expenses, WallachBeth Capital LLC announced.
Notes carry $4.1 million principal and a June 2027 maturity
The 17.5% OID Notes have an aggregate principal amount of $4,106,060 and mature on June 30, 2027. Investors in the securities purchase agreement are institutional and other accredited investors.
The notes become convertible into ABVC common stock after the eight-month anniversary of issuance. The conversion price is 85% of the average of the three VWAPs for the three trading days immediately before conversion, subject to a floor price and adjustments set out in the notes.